327 related articles for article (PubMed ID: 12456792)
21. Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1.
Stenoien DL; Mancini MG; Patel K; Allegretto EA; Smith CL; Mancini MA
Mol Endocrinol; 2000 Apr; 14(4):518-34. PubMed ID: 10770489
[TBL] [Abstract][Full Text] [Related]
22. Interaction of tetrahydrocrysene ketone with estrogen receptors alpha and beta indicates conformational differences in the receptor subtypes.
Tyulmenkov VV; Klinge CM
Arch Biochem Biophys; 2000 Sep; 381(1):135-42. PubMed ID: 11019829
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding.
Rodriguez AL; Tamrazi A; Collins ML; Katzenellenbogen JA
J Med Chem; 2004 Jan; 47(3):600-11. PubMed ID: 14736241
[TBL] [Abstract][Full Text] [Related]
24. Development of peptide antagonists that target estrogen receptor beta-coactivator interactions.
Hall JM; Chang CY; McDonnell DP
Mol Endocrinol; 2000 Dec; 14(12):2010-23. PubMed ID: 11117531
[TBL] [Abstract][Full Text] [Related]
25. Selection of estrogen receptor beta- and thyroid hormone receptor beta-specific coactivator-mimetic peptides using recombinant peptide libraries.
Northrop JP; Nguyen D; Piplani S; Olivan SE; Kwan ST; Go NF; Hart CP; Schatz PJ
Mol Endocrinol; 2000 May; 14(5):605-22. PubMed ID: 10809226
[TBL] [Abstract][Full Text] [Related]
26. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.
Hall JM; McDonnell DP
Endocrinology; 1999 Dec; 140(12):5566-78. PubMed ID: 10579320
[TBL] [Abstract][Full Text] [Related]
27. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.
Greschik H; Flaig R; Renaud JP; Moras D
J Biol Chem; 2004 Aug; 279(32):33639-46. PubMed ID: 15161930
[TBL] [Abstract][Full Text] [Related]
28. Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha.
Preisler-Mashek MT; Solodin N; Stark BL; Tyriver MK; Alarid ET
Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E891-8. PubMed ID: 11882509
[TBL] [Abstract][Full Text] [Related]
29. Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres.
Iannone MA; Consler TG; Pearce KH; Stimmel JB; Parks DJ; Gray JG
Cytometry; 2001 Aug; 44(4):326-37. PubMed ID: 11500849
[TBL] [Abstract][Full Text] [Related]
30. Ligand-induced changes in estrogen receptor conformation as measured by site-directed spin labeling.
Hurth KM; Nilges MJ; Carlson KE; Tamrazi A; Belford RL; Katzenellenbogen JA
Biochemistry; 2004 Feb; 43(7):1891-907. PubMed ID: 14967030
[TBL] [Abstract][Full Text] [Related]
31. Analysis of ligand-dependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization.
Ozers MS; Ervin KM; Steffen CL; Fronczak JA; Lebakken CS; Carnahan KA; Lowery RG; Burke TJ
Mol Endocrinol; 2005 Jan; 19(1):25-34. PubMed ID: 15375189
[TBL] [Abstract][Full Text] [Related]
32. Ligand-selective interdomain conformations of estrogen receptor-alpha.
Padron A; Li L; Kofoed EM; Schaufele F
Mol Endocrinol; 2007 Jan; 21(1):49-61. PubMed ID: 17008385
[TBL] [Abstract][Full Text] [Related]
33. Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta.
Margeat E; Bourdoncle A; Margueron R; Poujol N; Cavaillès V; Royer C
J Mol Biol; 2003 Feb; 326(1):77-92. PubMed ID: 12547192
[TBL] [Abstract][Full Text] [Related]
34. Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor.
Kojetin DJ; Burris TP; Jensen EV; Khan SA
Endocr Relat Cancer; 2008 Dec; 15(4):851-70. PubMed ID: 18755852
[TBL] [Abstract][Full Text] [Related]
35. Characterization of bacterially expressed rat estrogen receptor beta ligand binding domain by mass spectrometry: structural comparison with estrogen receptor alpha.
Witkowska HE; Carlquist M; Engström O; Carlsson B; Bonn T; Gustafsson JA; Shackleton CH
Steroids; 1997; 62(8-9):621-31. PubMed ID: 9292936
[TBL] [Abstract][Full Text] [Related]
36. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.
Shiau AK; Barstad D; Loria PM; Cheng L; Kushner PJ; Agard DA; Greene GL
Cell; 1998 Dec; 95(7):927-37. PubMed ID: 9875847
[TBL] [Abstract][Full Text] [Related]
37. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.
Weis KE; Ekena K; Thomas JA; Lazennec G; Katzenellenbogen BS
Mol Endocrinol; 1996 Nov; 10(11):1388-98. PubMed ID: 8923465
[TBL] [Abstract][Full Text] [Related]
38. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism.
Shiau AK; Barstad D; Radek JT; Meyers MJ; Nettles KW; Katzenellenbogen BS; Katzenellenbogen JA; Agard DA; Greene GL
Nat Struct Biol; 2002 May; 9(5):359-64. PubMed ID: 11953755
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
[TBL] [Abstract][Full Text] [Related]
40. Synthetic 19-nortestosterone derivatives as estrogen receptor alpha subtype-selective ligands induce similar receptor conformational changes and steroid receptor coactivator recruitment than natural estrogens.
García-Becerra R; Borja-Cacho E; Cooney AJ; Smith CL; Lemus AE; Pérez-Palacios G; Larrea F
J Steroid Biochem Mol Biol; 2006 May; 99(2-3):108-14. PubMed ID: 16616843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
